(Albany, NY) Delveinsight has launched a new report on “Chronic Heart Failure – Market Insights, Epidemiology, and Market Forecast-2030″.

 

DelveInsight’s “Chronic Heart Failure – Market Insights, Epidemiology, and Market Forecast-2030“ report delivers an in-depth understanding of the Chronic Heart Failure, historical and forecasted epidemiology as well as the Chronic Heart Failure market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some of the key facts:

• As per the Delveinsight’s analysis, the total diagnosed prevalent cases of Heart Failure in 7MM was found to be 12,026,384 in 2017.
• Among 7MM, US reported the highest number of prevalent cases of with 6,192,189 cases in 2017.
• According to DelveInsight, it is estimated that the Gender-specific prevalent cases of Heart Failure in France were 652,877 in males and 453,694 in females in 2017.

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/chronic-heart-failure-market

 

Scope of Report:

• The report covers the descriptive overview of Chronic Heart Failure, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Chronic Heart Failure epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Heart Failure are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Chronic Heart Failure market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chronic Heart Failure market

 

Chronic heart failure, otherwise known as congestive heart failure or heart failure, is an ongoing inability of the heart to pump enough blood through the body to ensure a sufficient supply of oxygen. The causes of the condition vary, but some of the most common risk factors include old age, diabetes, high blood pressure and being overweight. Chronic heart failure is most common in men.

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/chronic-heart-failure-market

 

The most common symptoms of chronic heart failure include shortness of breath, tiredness, swelling of the legs and ankles, chest pain and a cough. It most commonly affects older people and people with other heart conditions and is typically treated with a combination of lifestyle and diet changes, and medications. Chronic heart failure is typically a long-term condition that gradually worsens over time. This is the feature that differentiates it from acute heart failure, which develops very suddenly. It cannot typically be cured, but symptoms can be managed effectively.

 

Top Company Profile Analysis in this Report

• Novartis AG
• Bayer AG
• Orion Corp
• Vifor Pharma Ltd
• Cytokinetics Inc
• GlaxoSmithKline Plc
• Eli Lilly and Co

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/chronic-heart-failure-market

 

Table Of Contents:

1. Key Insights

2. Executive Summary of Chronic Heart Failure

3. Competitive Intelligence Analysis for Chronic Heart Failure

4. Chronic Heart Failure: Market Overview at a Glance

4.1. Chronic Heart Failure Total Market Share (%) Distribution in 2017

4.2. Chronic Heart Failure Total Market Share (%) Distribution in 2030

5. Chronic Heart Failure: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Chronic Heart Failure Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Chronic Heart Failure Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Chronic Heart Failure Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Chronic Heart Failure Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Chronic Heart Failure Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Chronic Heart Failure Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Chronic Heart Failure Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Chronic Heart Failure Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Chronic Heart Failure Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Chronic Heart Failure Treatment and Management

8.2. Chronic Heart Failure Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Chronic Heart Failure Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Chronic Heart Failure: Seven Major Market Analysis

13.1. Key Findings

13.2. Chronic Heart Failure Market Size in 7MM

13.3. Chronic Heart Failure Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Chronic Heart Failure Total Market Size in the United States

15.1.2. Chronic Heart Failure Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Chronic Heart Failure Total Market Size in Germany

15.3.2. Chronic Heart Failure Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Chronic Heart Failure Total Market Size in France

15.4.2. Chronic Heart Failure Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Chronic Heart Failure Total Market Size in Italy

15.5.2. Chronic Heart Failure Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Chronic Heart Failure Total Market Size in Spain

15.6.2. Chronic Heart Failure Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Chronic Heart Failure Total Market Size in the United Kingdom

15.7.2. Chronic Heart Failure Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Chronic Heart Failure Total Market Size in Japan

15.8.3. Chronic Heart Failure Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Chronic Heart Failure

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Request for Detailed TOC: https://www.delveinsight.com/sample-request/chronic-heart-failure-market

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-heart-failure-market